| Click on "►" to expand:|
[×] Entry inhibitors
Emtricitabine/tenofovir/efavirenz (Atripla) is a fixed-dose combination drug for the treatment of HIV infection. All three active substances block the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses
 BRAND NAMES
 MECHANISM OF ACTION
Atripla is a combination of
- nucleoside analog HIV-1 reverse transcriptase inhibitor (Emtricitabine)
- nucleotide analog HIV-1 reverse transcriptase inhibitor (Tenofovir)
- non-nucleoside HIV-1 reverse transcriptase inhibitor (Efavirenz)
Atripla is used alone as a complete regimen, or with other anti-HIV-1 medicines, to treat HIV-1 infection in adults and children at least 12 years old who weigh at least 40 kg (88 lbs) (FDA)
Recommended dose in adults and pediatric patients (12 years of age and older and weighing at least 40 kg): One tablet once daily taken orally on an empty stomach. Dosing at bedtime is recommended to improve tolerability of nervous system symptoms.
 DOSAGE FORMS AND STRENGTHS
Tablet containing 600 mg of efavirenz, 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate.
- Previously demonstrated hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz
- Medications that should not be taken with Atripla are bepridil, cisapride, midazolam, pimozide, triazolam, dihydroergotamine, ergotamine and voriconazole.
- St. John's wort is known to reduce the effectiveness of Atripla, resulting in increased viral load and possible resistance to Atripla
 PREGNANCY AND LACTATION
Pregnancy Category D (US)
 SIDE EFFECTS
The most common side effects are dizziness, headache, diarrhea, nausea, vomiting, rash, asthenia, hypophosphatemia and elevated levels of creatine kinase.